Achillion Pharmaceuticals, Inc. (ACHN) Announces Oral Presentations Given At APASL 2014 Detailing Clinical Activity Of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV
3/14/2014 9:33:41 AM
NEW HAVEN, Conn., March 14, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two oral presentations were made at the 23rd Asian Pacific Association for the Study of the Liver (APASL) Conference 2014 in Brisbane, Australia. Updated Phase 2 clinical trial results evaluating a 150 mg loading dose followed by 50 mg once daily of ACH-3102 in combination with either once daily 200 mg or 400 mg of sovaprevir and twice daily ribavirin showed that 100% of patients achieved SVR12 (n=8) including subjects who had Y93 mutations at baseline.
Help employers find you! Check out all the jobs and post your resume.
comments powered by